Sixteen Iranian psychiatrists identified potential benefits of demedicalization of cannabis use disorder, including reduced stigma and patient empowerment, while warning of increased treatment challenges and dangerous normalization.
Addiction policy researchers, mental health professionals debating medicalization frameworks, cross-cultural drug policy scholars.
Iranian psychiatrists saw both promise (reduced stigma) and risk (normalization) in demedicalization of CUD
What the researchers found
Four main themes emerged: advantages of demedicalization (reduced stigma, enhanced patient empowerment, less dependence on pharmacological treatments), disadvantages (increased treatment challenges, worsened social damages), sociocultural impacts (improved social interactions, shifting cultural attitudes), and policy recommendations (modified legal approaches, comprehensive multifaceted treatment models).
Why it matters
As global cannabis policy evolves, the question of whether cannabis use disorder should remain a medical diagnosis has real implications for treatment access, insurance coverage, and social stigma. This study captures expert clinical perspectives from a country with strict prohibition, offering a counterpoint to Western-centric policy discussions.
The numbers in context
16 psychiatrists interviewed; 4 main themes identified; data collected in Iran under prohibition context.
How the study worked
Qualitative phenomenological study using in-depth semi-structured interviews with 16 Iranian psychiatrists experienced in addiction treatment, analyzed using inductive content analysis via the Graneheim and Lundman approach.
What this study cannot tell us
Small qualitative sample from a single country with strict cannabis prohibition, limiting generalizability. Psychiatrists' views may reflect the specific Iranian legal and cultural context. No patient or consumer perspectives were included.
How to read the evidence
Preliminary: Small qualitative study (16 participants) from a single country provides exploratory insights but limited generalizability.
When this study was published
Published in 2025.
The bigger picture
The demedicalization debate extends beyond cannabis to broader questions about how societies define and respond to substance use. The Iranian psychiatrists' balanced view, seeing both benefits and risks in moving away from a strictly medical model, reflects tensions felt in many countries.
Questions still open
- Would demedicalization reduce treatment-seeking behavior? How would insurance and healthcare systems adapt? Would a non-medical framework reduce stigma enough to offset potential decreases in treatment access?
Common questions
What does demedicalization of cannabis use disorder mean?
Why does Iran's perspective matter?
Read the original research
Psychiatrists' opinions about non-medicalization of cannabis use disorder in Iran.
Discover mental health, 5(1), 187
Citation
Namazi, Hamidreza; Sayyah, Mehdi. (2025). Psychiatrists' opinions about non-medicalization of cannabis use disorder in Iran.. Discover mental health, 5(1), 187. https://doi.org/10.1007/s44192-025-00326-y
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit